EQUITY RESEARCH - ANALYST MEETING



THAILAND / HEALTH CARE SERVICES

CHG TB





TARGET PRICE THB3.80 CLOSE THB2.68 UP/DOWNSIDE +41.8% TP vs CONSENSUS +13.6%

Key takeaways from analyst meeting

Highlights

- We attended a CHG analyst meeting and had a neutral view of the meeting.
- Management decreased its 2024 revenue growth target to 12% (vs 15% previously) due to lower-than-expected revenue growth in 3Q24.
- The OPD revenue of general patients in 3Q24 fell by 3% y-y for two crucial reasons. First, Thai Amdon (CHG's subsidiary in charge of supply chain management) has changed its business model from selling medicine and medical supplies to buyers outside CHG's network to selling to only hospitals under CHG, resulting in a THB30-40m decrease in revenue each quarter. However, the overall margin should improve from economies of scale. Second, CHG304 and Cholvaej reported slow growth.
- International patient revenue mix decreased from 4% to 3% due to lower Qatar patients.
- CHG decided to terminate the management contract with Pattaya City Hospital due to low profitability and high resource consumption. Therefore, revenue should decrease by THB60-70m per quarter or 3% of total revenue. However, net profit should decrease only THB5-6m per quarter due to the low NPM. CHG would reallocate some of the staff to improve other hospitals, including CHG304, which management expects a significant improvement in its profitability margin in 4Q24.
- CHG Mae Sot operation significantly improved in 3Q24, with revenue of THB60m (vs THB35m in 2Q24) and a narrower loss of THB11-12m (vs THB28m loss in 2Q24).
- CHG also plans for medical fee adjustment at the beginning of next year.

Recommendation

- Although core profit hit a record high in 3Q24 (excluding the Covid pandemic period), the share price plunged by 7-10% after its 3Q24 result announcement, possibly due to concern over lower-thanexpected revenue growth.
- We maintain a positive outlook on CHG despite headwinds. CHG still
 has robust projected revenue growth of 10-12%, and its EBITDA
 margin has significantly improved to 26% in 3Q24 (vs 23% in 3Q19).
 Besides, we expect this improvement to continue as the loss from
 CHG Mae Sot declines.
- CHG is trading at a cheap valuation of 21x 2025E P/E.

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	7,730	8,462	9,156	9,780
Net profit	1,046	1,203	1,388	1,527
EPS (THB)	0.10	0.11	0.13	0.14
vs Consensus (%)	-	7.8	13.0	11.1
EBITDA	1,822	2,067	2,313	2,518
Recurring net profit	1,046	1,203	1,388	1,527
Core EPS (THB)	0.10	0.11	0.13	0.14
EPS growth (%)	(62.4)	15.0	15.4	10.0
Core P/E (x)	28.2	24.5	21.2	19.3
Dividend yield (%)	2.6	2.4	2.8	3.1
EV/EBITDA (x)	16.1	14.0	12.3	11.0
Price/book (x)	3.9	3.7	3.4	3.2
Net debt/Equity (%)	(8.2)	(11.3)	(17.1)	(22.5)
ROE (%)	13.9	15.5	16.7	17.0



Share price performance	1 Month	3 Month	12 Month			
Absolute (%)	(9.5)	6.3	(10.7)			
Relative to country (%)	(6.4)	(1.2)	(11.7)			
Mkt cap (USD m)			851			
3m avg. daily turnover (USD m)			2.2			
Free float (%)			43			
Major shareholder Kannikar Plussind (1						
12m high/low (THB) 3.34/2						
Issued shares (m)			11,000.00			

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA
Fundamental Investment Analyst on Securities; License no. 080523
teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: CHG - 3Q24 results summary

	3Q23	4Q23	1Q24	2Q24	3Q24	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Revenue	2,093	2,123	2,021	1,985	2,309	16	10	7,730	8,462	9
Cost of sales (Incl. depreciation)	(1,486)	(1,580)	(1,498)	(1,559)	(1,593)	2	7	(5,723)	(6,196)	8
Gross profit	607	543	523	427	716	68	18	2,008	2,266	13
SG&A	(246)	(243)	(259)	(240)	(243)	1	(1)	(911)	(997)	9
Operating profit	361	300	264	186	473	153	31	1,097	1,269	16
Other operating income	77	65	85	70	74	6	(3)	284	295	4
Interest income	1	4	1	5	1			9	6	(30)
Equity income	(5)	(9)	(9)	(5)	(2)			(19)	(10)	(48)
EBIT	434	361	342	257	545	112	26	1,370	1,561	14
Interest expense	(7)	(9)	(5)	(9)	(9)	2	31	(24)	(18)	(26)
EBT	427	352	337	248	536	116	26	1,346	1,543	15
Income tax	(90)	(73)	(76)	(57)	(103)	81	14	(279)	(317)	14
Minority interests	(11)	(5)	3	0	(16)		51	(21)	(22)	5
Core profit	326	274	264	192	417	117	28	1,046	1,203	15
Extraordinaries										
Net income	326	274	264	192	417	117	28	1,046	1,203	15
Core EPS (THB)	0.03	0.02	0.02	0.02	0.04	117	28	0.10	0.11	15
No of share (m)	11,000	11,000	11,000	11,000	11,000	0	0	11,000	11,000	0
Cost (Excl. depreciation)	(1,370)	(1,459)	(1,377)	(1,434)	(1,466)	2	7	(5,282)	(5,693)	8
Depreciation & amortisation	(117)	(121)	(121)	(124)	(127)	2	8	(441)	(503)	14
EBITDA	554	486	470	381	674	77	21	1,822	2,067	13
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	29	26	26	22	31	10	2	26	27	1
SG&A/Revenue	12	11	13	12	11	(2)	(1)	12	12	0
EBITDA margin	26	23	23	19	29	10	3	24	24	1
Net profit margin	16	13	13	10	18	8	3	14	14	1
Operating stats	(y-y %)									
SSO revenue	8	11	11	(2)	27					
SSO registered members ('000)	529	530	537	542						
SSO revenue per head	5	8	9	(5)						
Cash-OPD revenue	(6)	24	19	15	(3)					
Cash-OPD visit number	2	11	10	4						
Cash-OPD revenue per head	(8)	12	8	10						
Cash-IPD revenue	24	22	19	12	5					
Cash-IPD admission number										
Casii-IPD adiilission number	29	29	10	5						

Sources: CHG; FSSIA estimates

Financial Statements

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	10,103	7,730	8,462	9,156	9,780
Cost of goods sold	(5,908)	(5,723)	(6,196)	(6,623)	(7,024)
Gross profit	4,195	2,008	2,266	2,533	2,756
Other operating income	305	284	295	304	313
Operating costs	(935)	(911)	(997)	(1,060)	(1,123)
Operating EBITDA	3,947	1,822	2,067	2,313	2,518
Depreciation	(382)	(441)	(503)	(536)	(571)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	3,565	1,381	1,565	1,777	1,946
Net financing costs	(10)	(15)	(12)	2	5
Associates	(1)	(19)	(10)	(4)	1
Recurring non-operating income	(1)	(19)	(10)	(4)	1
Non-recurring items	0	0	0	0	0
Profit before tax	3,554	1,346	1,543	1,776	1,952
Tax	(703)	(279)	(317)	(364)	(399)
Profit after tax	2,850	1,067	1,225	1,412	1,554
Minority interests	(72)	(21)	(22)	(24)	(26)
Preferred dividends	· · ·	• •	• •	• •	-
Other items	-	-	-	-	-
Reported net profit	2,778	1,046	1,203	1,388	1,527
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	2,778	1,046	1,203	1,388	1,527
Per share (THB)					
Recurring EPS *	0.25	0.10	0.11	0.13	0.14
Reported EPS	0.25	0.10	0.11	0.13	0.14
DPS	0.16	0.07	0.07	80.0	0.08
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth					
Revenue (%)	(14.0)	(23.5)	9.5	8.2	6.8
Operating EBITDA (%)	(30.1)	(53.8)	13.5	11.9	8.8
Operating EBIT (%)	(32.7)	(61.3)	13.3	13.6	9.5
Recurring EPS (%)	(33.9)	(62.4)	15.0	15.4	10.0
Reported EPS (%)	(33.9)	(62.4)	15.0	15.4	10.0
Operating performance					
Gross margin inc. depreciation (%)	41.5	26.0	26.8	27.7	28.2
Gross margin exc. depreciation (%)	45.3	31.7	32.7	33.5	34.0
Operating EBITDA margin (%)	39.1	23.6	24.4	25.3	25.7
Operating EBIT margin (%)	35.3	17.9	18.5	19.4	19.9
Net margin (%)	27.5	13.5	14.2	15.2	15.6
Effective tax rate (%)	19.8	20.4	20.4	20.4	20.4
Dividend payout on recurring profit (%)	63.3	73.6	60.0	60.0	60.0
Interest cover (X)	349.5	88.7	132.8	(784.4)	(399.2)
Inventory days	18.5	20.8	22.4	22.5	22.6
Debtor days	24.8	38.5	39.5	38.2	35.8
Creditor days	55.9	60.3	59.5	59.8	60.0
Operating ROIC (%)	47.1	15.9	17.1	19.1	20.8
ROIC (%)	45.1	14.9	16.3	18.3	20.0
ROE (%)	36.8	13.9	15.5	16.7	17.0
ROA (%)	27.4	10.5	12.1	13.4	13.7
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	5,160	5,025	5,646	6,225	6,733
SSO patient revenue	2,149	2,461	2,560	2,663	2,770

Sources: Chularat Hospital; FSSIA estimates

Financial Statements

Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,778	1,046	1,203	1,388	1,527
Depreciation	382	441	503	536	57
Associates & minorities	-	-	-	-	0.1
Other non-cash items	117	30 435	22	24	20
Change in working capital Cash flow from operations	(696) 2,582	435 1,951	(135) 1,593	(48) 1,900	(42 2,08 3
Capex - maintenance	(777)	(1,451)	(508)	(549)	(587
Capex - new investment	(111)	(1,451)	(506)	(549)	(307
Net acquisitions & disposals	(142)	19	0	0	(
Other investments (net)	(1-12)	-	-	-	`
Cash flow from investing	(919)	(1,432)	(508)	(549)	(587
Dividends paid	(2,805)	(1,045)	(770)	(722)	(833
Equity finance	0	0	0	0	(000)
Debt finance	356	(120)	(705)	0	(
Other financing cash flows	(3)	44	(22)	(24)	(26
Cash flow from financing	(2,452)	(1,121)	(1,497)	(746)	(859
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
Net other adjustments	0	0	0	0	(
Movement in cash	(789)	(601)	(412)	605	637
Free cash flow to firm (FCFF)	1,679.02	543.33	1,103.00	1,353.13	1,498.47
Free cash flow to equity (FCFE)	2,016.07	443.25	357.95	1,326.62	1,470.0
Per share (THB)					
FCFF per share	0.15	0.05	0.10	0.12	0.14
FCFE per share	0.18	0.04	0.03	0.12	0.13
Recurring cash flow per share	0.30	0.14	0.16	0.18	0.19
Salance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
, , , , , , , , , , , , , , , , , , ,					
Tangible fixed assets (gross)	7,867	9,318	9,825	10,375	10,962
Less: Accumulated depreciation	(2,987)	(3,414)	(3,917)	(4,453)	(5,024
Tangible fixed assets (net)	4,880	5,903	5,908	5,922	5,937
ntangible fixed assets (net)	47	104	104	104	10-
Long-term financial assets	-	-	-	-	40
nvest. in associates & subsidiaries	142	122	122	122	12:
Cash & equivalents	2,001	1,399	987	1,592	2,229
A/C receivable	757	874	959	959	959
nventories Other current assets	265 2,036	336 1,436	363 1,572	388 1,701	41 ⁻ 1,81 ⁻
Ourrent assets	5,058	4,046	3,880	4,639	5,41
Other assets	152	4,046 88	3,880 88	4,039 88	3,410
Total assets	10,280	10,264	10,104	10,876	11,66
Common equity	7,523	7,525	7,958	8,624	9,31
Minorities etc.	341	406	406	406	40
Total shareholders' equity	7,864	7,931	8,364	9,030	9,72
ong term debt	470	705	0	0	-,
Other long-term liabilities	233	247	247	247	24
Long-term liabilities	704	953	247	247	24
A/C payable	851	894	963	1,030	1,09
Short term debt	400	45	45	45	4
Other current liabilities	462	442	484	524	55
Current liabilities	1,712	1,381	1,492	1,599	1,69
Total liabilities and shareholders' equity	10,280	10,264	10,104	10,876	11,66
Net working capital	1,745	1,311	1,446	1,494	1,53
nvested capital	6,967	7,529	7,669	7,731	7,78
Includes convertibles and preferred stock which is be	ing treated as debt				
Per share (THB)					
Book value per share	0.68	0.68	0.72	0.78	0.8
Fangible book value per share	0.68	0.67	0.71	0.77	0.8
Financial strength					2.0
Net debt/equity (%)	(14.4)	(8.2)	(11.3)	(17.1)	(22.5
Net debt/total assets (%)	(11.0)	(6.3)	(9.3)	(14.2)	(18.7
Current ratio (x)	3.0	2.9	2.6	2.9	3.
CF interest cover (x)	198.7	29.9	31.6	(585.6)	(300.4
/aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	10.6	28.2	24.5	21.2	19.
Recurring P/E @ target price (x) *	15.0	40.0	34.7	30.1	27.
Reported P/E (x)	10.6	28.2	24.5	21.2	19.
Dividend yield (%)	6.0	2.6	2.4	2.8	3
Price/book (x)	3.9	3.9	3.7	3.4	3.
Price/tangible book (x)	3.9	4.0	3.8	3.5	3
			440	40.0	11
EV/EBITDA (x) **	7.3	16.1	14.0	12.3	11.
	7.3 10.4 4.1	16.1 22.8 3.9	20.0 3.8	17.6 3.7	15.

Sources: Chularat Hospital; FSSIA estimates

Chularat Hospital PCL (CHG TB)



Exhibit 2: FSSIA ESG score implication

38.25 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings						Bloomberg	
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
вн	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High		-			17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	_	2.21	2.34
BESG environmental pillar score		_	4.04	4.18
BESG social pillar score	_	_	0.74	0.79
BESG governance pillar score	_	_	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	_	_	_	_
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	_	_	_	_
Renewable energy use	_	_	_	_
Electricity used	4	4	4	7
Fuel used - natural gas	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No
Waste reduction policy	Yes	Yes	Yes	Yes
Hazardous waste	0	0	0	(
Total waste	1	1	1	•
Waste recycled	0	0	0	(
Waste sent to landfills	_	_	_	_
Environmental supply chain management	No	No	No	No
Water policy	No	No	Yes	Yes
Water consumption	89	73	80	70
Social				
Human rights policy	Yes	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Yes	Ye
Quality assurance and recall policy	No	No	No	N
Consumer data protection policy	Yes	Yes	Yes	Ye
Equal opportunity policy	Yes	Yes	Yes	Ye
Gender pay gap breakout	No	No	No	N
Pct women in workforce	_	_	84	8
Pct disabled in workforce	_	_	_	-
Business ethics policy	Yes	Yes	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Yes	Ye
Health and safety policy	Yes	Yes	Yes	Ye
Lost time incident rate - employees	_	_	_	
Total recordable incident rate - employees	_	_	_	_
Training policy	Yes	Yes	Yes	Ye
Fair remuneration policy	No	No	No	N
Number of employees – CSR	3,612	3,616	3,871	4,52
Employee turnover pct		-	20	2
Total hours spent by firm - employee training	_	_	32,904	85,88
Social supply chain management	No	No	No	00,00 N
Governance				
Board size	12	12	12	1
No. of independent directors (ID)	4	4	4	_
No. of women on board	2	2	2	
No. of non-executive directors on board	11	11	11	1
Company conducts board evaluations	Yes	Yes	Yes	Ye
No. of board meetings for the year	6	7	7	10
Board meeting attendance pct	100	100	95	10
	3	3	3	10
Board duration (years)	No	No	No	N
Director share ownership guidelines				
Age of the youngest director	60	62	63	5
Age of the oldest director	77	78	79	8
No. of executives / company managers	6	6	6	
No. of female executives	2	2	2	
Executive share ownership guidelines	No	No	No	N
Size of audit committee	3	3	3	
No. of ID on audit committee	3	3	3	
Audit committee meetings	5	5	5	
Audit meeting attendance %	100	100	100	10
Size of compensation committee	5	5	5	
No. of ID on compensation committee	4	4	4	
No. of compensation committee meetings	2	2	2	
Compensation meeting attendance %	100	100	83	10
Size of nomination committee	5	5	5	
No. of nomination committee meetings	2	2	2	
Nomination meeting attendance %	100	100	83	10
Sustainability governance				
Verification type	No	No	No	N

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann	ed on the com ual S&P Glob	transparent, rules-based ipanies' Total Sustainabili al Corporate Sustainabili anies within each industry	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	ssessment (C ess than 45% ny are disquali	ne annual S&P (SA) for DJSI. Co of the S&P Glob fied. The constit verse.	mpanies with al ESG Score	an S&P Globa of the highest	
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing bu Candidates r 1) no irregula float of >150 up capital. So 70%; 2) inde wrongdoing r	isiness with tr must pass the ar trading of th shareholders ome key disqu pendent direct related to CG,	nsibility in Environmental ansparency in Governand preemptive criteria, with the board members and extended on an and combined holding the criteria include: 1 tors and free float violatic social & environmental in arnings in red for > 3 year	ce, updated annually. two crucial conditions: xecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>SETESG inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETESG Index</u> is extended from the SET ESG Ratings companies whos 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3 liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	h in sustainable developn with support from the Sto ts are from the perspectiv s.	ck Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores below nent of shareh 5%); 4) disclo	ories: 5 for Excel -79), 2 for Fair (6 w 50. Weightings olders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) an); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of si exercised. The and verifiability	e incorporated and sufficiently e CG compon AGM proced and after the r ufficient informa second assess c; and 3) openne	which shareholders' rights into business operations y disclosed. All form impoents to be evaluated annures before the meeting (10%). (The first attion for voting; and 2) facilitations in the ease of attending mess for Q&A. The third involvees, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be leetings; 2) transparency is the meeting minutes that			four categories: (80-89), and not			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of a Certification, in managers and	nt of key contr Certification i eciding to becom Intent to kick off cluding risk ass	Checklist include corruptions, and the monitoring as good for three years. Be a CAC certified member st an 18-month deadline to subsessment, in place of policy are ablishment of whistleblowing at takeholders.)	nd developing of tart by submitting a mit the CAC Checklist for and control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unmar regulatory filing information, co.	assessment of naged. Sources gs, news and off mpany feedback	sk rating provides an ove of how much of a compar is to be reviewed include corp her media, NGO reports/webs k, ESG controversies, issuer i	ny's exposure to ESG orate publications and sites, multi-sector			score is the sum higher ESG risk Medium		ed risk. The	
	reports, and qu	iality & peer revi	iews.		0-10	10-20	20-30	30-40	40+	
ESG Book	positioned to the principle helps explain over-weightin	outperform o of financial m future risk-ad	sustainable companies th wer the long term. The materiality including information in djusted performance. Mat th higher materiality and orthy orly basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s dicating better p	core is scaled		
MSCI .			measure a company's mand laggards according to						ethodology to	
	AAA	8.571-10.00	00 0	their exposure to 200 he	no and now wen	they manage	triose risks relat	ve to peers.		
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most si	gnificant ESG ris	sks and opportunitie	es		
	Α	5.714-7.142	2							
	ввв	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of ma	anaging the mos	t significant ESG ris	sks and opportu	nities relative to	
	ВВ	2.857-4.285	5	, 2000						
	В	1.429-2.856	Laggard:	lagging its industry base	d on its high evace	ure and failure to	manage significar	t ESG risks		
	ccc	0.000-1.428		lagging its industry base	on no mgn expus	o unu ialluit li	anage agrilledi	1131/3		
Moody's ESG solutions	believes that	a company ir	gree to which companies integrating ESG factors into or shareholders over the i	to its business model and						
Refinitiv ESG rating	based on pul	blicly available	and objectively measure e and auditable data. The ta publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performan	ce and insufficie	nt degree of ti		
S&P Global			re is a relative score mea				of ESG risks, op	portunities, an	d impacts	
Bloomberg	ESG Score	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.								
			of Pillar Scores, where t	ine weights are determin	ed by the pilial p	nonty ranking.	values rarrye in	JIII 0 10 10, 10	is the best.	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION


Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
11-Feb-2022 09-Feb-2023 03-Aug-2023	BUY BUY BUY	4.70 4.40 3.90	03-Nov-2023 30-Jan-2024 17-Jul-2024	BUY BUY BUY	4.00 3.90 3.60	29-Oct-2024	BUY	3.80

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 2.68	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 21-Nov-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.